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Abstract: Our aim was to characterize and validate that the location and age of onset of the tumor
are both important criteria to classify colorectal cancer (CRC). We analyzed clinical and molecular
characteristics of early-onset CRC (EOCRC) and late-onset CRC (LOCRC), and we compared each
tumor location between both ages-of-onset. In right-sided colon tumors, early-onset cases showed
extensive Lynch syndrome (LS) features, with a relatively low frequency of chromosomal instability
(CIN), but a high CpG island methylation phenotype. Nevertheless, late-onset cases showed
predominantly sporadic features and microsatellite instability cases due to BRAF mutations. In left
colon cancers, the most reliable clinical features were the tendency to develop polyps as well as
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multiple primary CRC associated with the late-onset subset. Apart from the higher degree of CIN in
left-sided early-onset cancers, differential copy number alterations were also observed. Differences
among rectal cancers showed that early-onset rectal cancers were diagnosed at later stages, had less
association with polyps, and more than half of them were associated with a familial LS component.
Stratifying CRC according to both location and age-of-onset criteria is meaningful, not only because
it correlates the resulting categories with certain molecular bases, but with the confirmation across
larger studies, new therapeutical algorithms could be defined according to this subclassification.
Keywords: early-onset colorectal cancer; late-onset colorectal cancer; microsatellite instability;
chromosomal instability; CpG island methylator phenotype; tumor location.
1. Introduction
In Europe, colorectal cancer (CRC) is the third most common cancer in males, the second most
common cancer in females, and the fourth most common cause of cancer-related deaths; worldwide,
1,360,000 new cases are diagnosed each year and it causes 700,000 deaths [1]. Biologically, it represents a
heterogeneous disease. Early-onset colorectal cancer (EOCRC) represents 11% of colon cancers and 18%
of rectal cancers, and its incidence is increasing [2]. Several studies have described different genetics,
biological and clinical behavior in this age group, suggesting that it may be a specific subgroup within
CRC, and that age-of-onset should be a major criterion for its subclassification [3,4]. Moreover, new
findings may also define some particular subtypes, such as rectal cancer with microsatellite-stability
(MSS) and without chromosomal instability (CIN-) [5].
The predisposition of the three main carcinogenetic CRC pathways to different locations in
the colon, together with studies demonstrating that right and left-sided CRCs exhibit different
genetic, biological and demographical characteristics and risk factors, suggest that the carcinogenetic
mechanism and progression of CRC may differ with tumor location. Thus, the anatomic site of origin of
CRC appears to be another good discriminator for the subclassification of this type of neoplasm [6–8].
Along these lines, we recently analyzed tumor location (right colon, left colon and rectum) as a
discriminatory factor within EOCRC and clinical differences emerged as well as the different main
carcinogenetic pathways predominant within each location [9].
For the past few years, while characterizing EOCRC from different points of view, we have
been comparing series of features with their correlates in late-onset CRC (LOCRC) in order to assess
whether they have a different molecular basis [3,4,10]. Therefore, our purpose at this point is to confirm
whether our previous findings that the differential clinical and molecular features of tumors with a
different location in CRC and the age-of-onset as a major criterion to classify CRC, hold up together.
If so, right colon, left colon and rectal cancers should be substantially different between early and late
age-of-onset groups.
2. Results
2.1. EOCRC: Global Group Features and Comparative Analysis According to Colon Location
2.1.1. Clinicopathological and Familial Features
Comparative analysis of EOCRC with respect to tumor location has been published before [9].
Left colon was the most frequent location (43%), followed by rectum (33%). The main features for each
location are shown in Tables 1–3.
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Table 1. Comparison between right colon cancers with different ages of onset.
RIGHT COLON n/NEOCRC
EARLY-ONSET
n/Right-sided EOCC (%)
n/N
LOCRC
LATE-ONSET
n/ Right-sided LOCC (%) p(χ
2)
Number of cases (%) 20/82 24% 38/97 39%
Age of Onset (mean (SD), years) 1 - 39.1 (6) - 79.08 (5) NS
Gender 10/82 Female 10/20 (50%) 25/97 Female 25/38 (66%) NS
Grade of tumor differentiation (%) 2 5/82 Poor 5/20 (25%) 24/97 Medium 24/38 (63%) NS
Mucosecretion2 7/82 7/20 (35%) 13/97 13/38 (34%) NS
Presence of “Signet-ring” cells 2 0/82 0/20 (0%) 0/97 0/38 (0%) NS
TNM (UICC) Stage (%) 16/82 I-II: 16/20 (80%) 30/97 II-III: 30/38 (79%) NS
Associated Polyps 7/82 14/20 (70%) 19/97 24/38 (63%) NS
Mean number of associated polyps 1 - 3 - 1.8 0.021
Type of associated polyps (%) 10/82 Mixed: 10/20 (50%) 21/97 Adenomatous: 21/38 (54%) NS
S- and/or MCRC 4/82 4/20 (20%) 9/97 9/38 (24%) NS
Amsterdam criteria for LS 8/82 8/20 (40%) 1/97 1/38 (3%) <0.001
Familial aggregation for LS-related neoplasms 7/82 7/20 (35%) 6/97 6/38 (16%) 0.008
Familial aggregation for LS-unrelated neoplasms 1/82 1/20 (5%) 1/97 1/38 (3%) NS
Sporadic cases 4/82 4/20 (20%) 28/97 28/38 (74%) <0.001
Disease-Free Survival (mean; months) 1 - 72.4 - 20.16 0.002
Global Survival (mean; months) 1 - 81.06 - 45.94 0.003
MSI 6/82 6/20 (30%) 7/38 7/38 (18%) NS
MMR genes germline mutations 6/82 6/20 (30%) 5/97 5/ 38 (13%) NS
BRAF mutation 0/82 0/82 (0%) 5/97 5/38 (13%) NS
CIMP Classification (%) 2
0.025
High 8/78 8/16 (50%) 7/90 7/36 (20%)
Low 6/78 6/16 (37.5%) 12/90 12/36 (33%)
0 2/78 2/16 (12.5%) 17/90 17/36 (47%)
Molecular Classification (%) 2
MSI-CIMP-High 3/82 3/16 (19%) 5/90 5/36 (14%) 0.019
MSI-CIMP0 2/82 2/16 (12.5%) 2/90 2/36 (5%)
MSS-CIMP-High 5/82 5/16 (31%) 2/90 2/36 (5%)
MSS-CIMP0 6/82 6/16 (37.5%) 27/90 27/36 (75%)
Genomic instability1
GII Gain 0.144296 0.183649 NS
GII Loss 0.058762 0.249820 0.003
GII Normal 0.796933 0.566522 0.03
Mean Gained Chromosomes 1.38 1.80 NS
Mean Lost Chromosomes 1.08 2.20 0.018
1 Statistical analysis was carried out using Student’s t-test. 2 It has been carried out on the maximum number of patients with the specimen available. EOCC: Early-onset colon cancer;
EOCRC: Early-onset colorectal cancer; LOCC: Late-onset colon cancer: LOCRC: Late-onset colorectal cancer; NS: Not significant; SD: Standard deviation; UICC: International Union
Against Cancer; S- and/or MCRC: synchronous and/or metachronous; LS: Lynch syndrome; MMR: Mismatch repair; MSI: Microsatellite instability; CIMP: CpG island methylator
phenotype; MSS: Microsatellite stable; GII: Genomic instability index.
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Table 2. Comparison between left colon cancers with different ages of onset.
LEFT COLON n/NEOCRC
EARLY-ONSET
n/Left colon EOCC (%)
n/N
LOCR
LATE-ONSET
n/ Left colon EOCC (%) p(χ
2)
Number of cases (%) 35/82 43% 22/97 22.7%
Age of Onset (mean (SD), years) 1 - 39.3 (4.2) - 74.86 (5) NS
Gender (%) 22/82 Male 22/35 (63%) 14/97 Male 14/22 (64%) NS
Grade of tumor differentiation (%) 2 24/82 Medium 24/35 (68.5%) 17/97 Medium 17/22 (77%) NS
Mucosecretion 2 8/82 8/24 (33%) 2/97 2/22 (9.1%) NS
Presence of “Signet-ring” cells 2 2/82 2/24 (8%) 0/97 0/22 (0%) NS
TNM Stage (%) 27/82 I/II 27/35 (77%) 18/97 II-III 18/22 (82%) 0.003
Associated polyps 21/82 21/35 (60%) 13/97 13/22 (59.1%) NS
Mean number of associated polyps 1 - 1.6 - 5.41 <0.001
Type of associated polyps (%) 10/82 Adenomatous 10/21 (48%) 7/97 Adenomatous 7/13 (54%) NS
S- and/or MCRC 0/82 0/35 8/97 8/22 (36%) <0.001
Amsterdam criteria for LS 6/82 6/35 (17%) 0/97 0/22 (0%) NS
Familial aggregation for LS-related neoplasms 6/82 6/35 (17%) 6/97 6/22 (27%) NS
Familial aggregation for LS-unrelated neoplasms 6/82 6/35 (17%) 2/97 2/22 (9%) NS
Sporadic cases 17/82 17/35 (48%) 12/97 12/22 (55%) NS
Disease-Free Survival (mean; months) 1 - 48.70 - 31.68 NS
Global Survival (mean; months) 1 - 76.67 - 96.95 NS
MSI 6/82 6/35 (17%) 2/97 2/22 (9%) NS
MMR gene germline mutations 4/82 4/35 (11%) 0/97 0/22 (0%) NS
BRAF mutation 1/82 1/35 (3%) 1/97 1/22 (4.5%) NS
CIMP Classification (%) 2
High 3/78 3/31 (10%) 3/96 3/21 (14%) NS
Low 14/78 14/31 (45%) 4/96 4/21 (19%)
0 14/78 14/31 (45%) 14/96 14/21 (67%)
Molecular Classification (%) 2
MSI-CIMP-High 1/78 1/31 (3%) 2/96 2/21 (9.5%) NS
MSI-CIMP0 4/78 4/31 (13%) 0/96 0/21 (0%)
MSS-CIMP-High 2/78 2/31 (6.5%) 1/96 1/21 (5%)
MSS-CIMP0 24/78 24/31 (77.5%) 18/96 18/21 (86%)
Genomic instability 1
GII Gain 0.1462817 0.101056 NS
GII Loss 0.2294307 0.114539 0.06
GII Normal 0.6247970 0.784362 NS
Mean Gained Chromosomes 2.00 0.78 0.03
Mean Lost Chromosomes 1.93 0.61 0.03
1 Statistical analysis was carried out using Student’s t-test. 2 It has been carried out on the maximum number of patients with the specimen available. EOCC: Early-onset colon cancer;
EOCRC: Early-onset colorectal cancer; LOCC: Late-onset colon cancer; LOCRC: Late-onset colorectal cancer; NS: Not significant; SD: Standard deviation; UICC: International Union
Against Cancer; S- and/or MCRC: synchronous and/or metachronous; LS: Lynch syndrome; MMR: Mismatch repair; MSI: Microsatellite instability; CIMP: CpG island methylator
phenotype; MSS: Microsatellite stable; GII: Genomic instability index
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Table 3. Comparison between rectal cancers with different ages of onset.
RECTUM n/NEOCRC
EARLY-ONSET
n/ EORC (%)
n/N
LOCRC
LATE-ONSET
n/ LORC (%) p(χ
2)
Number of cases (%) 27/82 33% 37/97 38.1%
Age of Onset (mean (SD), years) 1 - 40.2 (5) - 78.54 (5) NS
Gender (%) 17/82 Male 17/27 (63%) 23/97 Male 23/37 (62%) NS
Grade of tumoral differentiation (%)2 18/82 Medium 18/27 (68%) 29/97 Medium 29/37 (79%) NS
Mucosecretion2 5/75 5/20 (25%) 4/97 4/34 (11.8%) NS
Presence of Signet-ring cells2 2/75 2/20 (10%) 0/97 0/37 (0%) NS
TNM Stage (%) 10/82 IV 10/27 (37%) 18/97 II 18/37 (49%) 0.002
Associated Polyps 11/82 11/27 (41%) 25/97 25/37 (68%) 0.04
Mean number of associated polyps1 - 1.22 - 2.00 NS
Type of associated polyps (%) 7/66 Adenomatous: 7/11 (64%) 18/85 Adenomatous: 18/25 (72%) NS
S- and/or MCRC 0/82 0/27 (0) 4/97 4/37 (11%) NS
Amsterdam criteria for LS 1/82 1/27 (4%) 0/97 0/37 (0) NS
Familial aggregation for LS-related neoplasms 14/82 14/ 27 (52%) 0/97 0/37 (0) <0.001
Familial aggregation for LS-unrelated neoplasms 2/82 2/27 (7%) 3/97 3/37 (8%) NS
Sporadic Cases 10/82 10/27 (37%) 34/97 34/37 (92%) <0.001
Disease-Free Survival (mean; months)1 - 35.85 - 16.25 <0.001
Global Survival (mean; months)1 - 64.79 - 31.67 <0.001
Microsatellite stability: 0/82 0/27 0/97 0/37 NS
MMR gene germline mutations 0/82 0/27 0/97 0/27 NS
BRAF mutation 0/82 0/27 1/97 1/37 (2.7%) NS
CIMP Classification (%)2 NS
High 2/76 2/21 (10%) 12/93 12/33 (36%)
Low 8/76 8/21 (38%) 9/93 8/33 (24%)
0 11/76 11/21 (52%) 13/93 13/33 (40%)
Molecular Classification (%)2 0.035
MSI-CIMP-High 0/76 0/21 0/93 0/33
MSI-CIMP0 0/76 0/21 0/93 0/33
MSS-CIMP-High 2/76 2/21 (9%) 12/93 12/33 (36%)
MSS-CIMP0 19/76 19/21 (90.5%) 21/93 21/33 (64%)
Genomic instability 1
GII Gain 0.1627359 0.133332 NS
GII Loss 0.1441914 0.194276 NS
GII Normal 0.6930648 0.672383 NS
Mean Gained Chromosomes 2.37 1.67 NS
Mean Lost Chromosomes 1.26 2.09 NS
1 Statistical analysis was carried out using Student’s t test. 2 It has been carried out on the maximum number of patients with the specimen available. EOCRC: Early-onset colorectal cancer;
EORC: Early-onset rectal cancer: LOCRC: Late-onset colorectal cancer; LORC: Late-onset rectal cancer; NS: Not significant; SD: Standard deviation; UICC: International Union Against
Cancer; S- and/or MCRC: synchronous and/or metachronous; LS: Lynch syndrome; MMR: Mismatch repair; MSI: Microsatellite Instability; CIMP: CpG island methylator phenotype; MSS:
Microsatellite stable; GII: Genomic instability index.
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2.1.2. Molecular Features
Approximately 15% of EOCRC tumors showed Microsatellite Instability (MSI); the most prevalent
location was the right colon (30%), followed by the left colon (17%). None of the tumors located at the
rectum showed MSI. Most MSI cases were due to LS (germline mutations in MMR genes). CIMP-high
was also located mainly in the right colon (50%). Therefore, according to the molecular classification,
the most homogeneous distribution was observed for right colon cancers. For left colon and rectal
cancers, the largest category was MSS-CIMP-Low/0 (77.5% and 90.5%, respectively). Right colon
tumors showed the lower CIN, whereas left colon tumors exhibited the highest CIN, particularly with
respect to losses. Rectal tumors showed the highest mean number of whole chromosome aberrations.
As we published before, recurrent gains and losses were more frequent in right-sided early-onset
colon cancers (EOCCs) [9]. The only recurrent region that was observed in all three tumor locations
was the gain of 19p13.3-q13.24. Five regions were common to right- and left-sided EOCCs: losses at
1q12-q21.2, 5q13.2, 9p12-p13, 9p13.1, and 10q11.22. Other frequently altered regions were: gains at
7q22.1 and losses at 16p13.12-p12.3 in right-sided EOCCs; losses at 9q21.11 and 11q14.2-14.3, and gains
at 20q11.21-q11.22 in left-sided EOCCs; losses at 14q11.1-11.2, and gains at 17q21.31-q21.32 and 22q11.1
in early-onset rectal cancers (EORCs) [9].
2.2. LOCRC: Global Group Features and Comparative Analysis According to Colon Location
2.2.1. Clinico-Pathological and Familial Features
Clinical and molecular features of global LOCRC and comparison between colon locations have
been published before [4,9–11], and are summarized in Tables 1–3. The least frequent location was left
colon (23%), whereas the other two locations were observed at equivalent rates.
2.2.2. Molecular Features
With regard to the three main molecular carcinogenetic pathways, nine cases showed MSI (9.3%),
with only one of them due to an MMR-germline mutation; seven of the others were due to BRAF
mutations and/or hypermethylation of the MLH1 promoter, the majority of which were located in
the right colon. With regard to the molecular classification, the highest proportion was related to
MSS-CIMP-Low-0, reaching almost 86% of all left colon cancers. Interestingly, another frequently
occurring molecular classification was MSS-CIMP-High in rectal tumors, reaching 36%. The highest
CIN was observed in the right colon. Left colon cancers showed an interestingly low CIN, and rectal
tumors showed a high mean of whole altered chromosomes.
Recurrent gains and losses were slightly more frequent in right-sided late-onset colon cancers
(LOCCs), followed by rectal cases. The only recurrent regions that were observed in all three tumor
locations were gains of 7q11.22-11.23 and 20q11.1-q11.23. Four regions were common to right- and
left-sided LOCCs: losses at 18q12.1-12.2, 18q21.1 and 18q22.1-23, and gains at 7p22.1. Only two regions
were common to left-sided LOCCs and late-onset rectal cancers (LORCs): losses at 5p15.33-15.31 and
alterations in 1q21.1-21.2. Finally, a high proportion of altered regions were common between the right
colon and rectal cancers. Individually, the most frequently altered regions for each location were gains
at 7q11.21 and 7q11.23, and losses at 18q22.1-22.3 in right-sided LOCCs; losses at 10q11.21-11.23 in
left-sided LOCCs; gains at 7q11.22-11.23 in LORCs.
2.3. Right Colon Cancers: Comparison between EOCC and LOCC
2.3.1. Clinico-Pathological and Familial Features
We compared right colon cancers between both age-of-onset populations (Table 1). The right
colon location was more frequent in LOCRC (39% vs 24%). Most of the differential features related
to the early-onset subset were because of the LS component: cases were diagnosed at early stages,
with a higher mean number of polyps during follow-up and showed an important familial component.
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They also showed a better disease-free survival (DFS). On the other hand, late-onset cases developed
on average fewer polyps during follow-up, and three-quarters of them were sporadic.
2.3.2. Molecular Features
With respect to the molecular component of right-sided EOCC, all MSI tumors were due to
germline mutations in the MMR genes (30%), with the genomic instability index (GII) being equivalent
to a low CIN. Of note, there is a considerable component of CIMP-High in this particular group. All of
these features are shown in Table 1. Within right-sided LOCC, the MSI component (18%) was almost
entirely due to BRAF mutations and/or hypermethylation of the MLH1 promoter; these cases display
some already known particular characteristics, such as a CIMP-High component [12]. This subset
showed a much higher CIN compared with its EOCC equivalent, as shown in Figure 1A.
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The right colon is the location with most differentially altered chromosomal segments according
to the age of onset, mainly for the late-onset group (Table S1), and the most frequent specific differential
segments for each location are shown in Table 4. From a total of 113 differentially altered chromosomal
segments, 100 corresponded to right-sided LOCC, and losses in chr2 and gains in chr7 were the most
frequent. Only 13 differential segments were particularly predominant in right-sided EOCC, in most
cases corresponding to losses in 1q21.1-21.2, 10q11.21-11.22 and 14q11.1-11.2.
2.4. Left Colon Cancers: Comparison between EOCC and LOCC
2.4.1. Clinico-Pathological and Familial Features
The age subset with the highest proportion of left colon cancers was EOCRC (43%). Most of
the clinicopathological and familial features were similar for both groups, as shown in Table 2.
The earlier stages at diagnosis in the left-sided EOCC group (80% for stages I and II), and the
higher development of polyps as well as other CRCs (S and/or MCRC) in left-sided LOCC were
the differential characteristics.
2.4.2. Molecular Features
The higher CIN in the early-onset subgroup is noteworthy (Figure 1B and Table 2). A very low
number of differentially altered chromosomal segments between the age-of-onset groups was observed,
mainly in the early-onset subset. Differential segments are listed in Table S1 and summarized in Table 4.
In early-onset subgroup, losses were present in most cases: in 1p12-q21.1, 5q13.1-13.2, 9p12-q24.22,
9q31.3-33.1, 11p11.12-q12.1 and 11q14.41-14.3, as well as a gain in 19p13.12-12.
2.5. Rectal Cancers: Comparison between EORC and LORC
2.5.1. Clinicopathological and Familial Features
Table 3 summarizes the main differential features between rectal cancers of both age-groups.
From a clinical point of view, EORCs showed less association with polyps, a very advanced stage at
diagnosis (37% with metastasis), and a better DFS; a relevant aspect was the important familial cancer
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component, with more than 50% of cases with LS-related neoplasms in their families. Conversely,
LORC cases were mainly sporadic.
2.5.2. Molecular Features
All LORCs were MSS, and an important number of these tumors showed CIMP-High (36%).
More than 90% of EORC were MSS-CIMP0. Lastly, there were differences in relation to CIN, with the
young rectal cancers displaying less instability for losses (Figure 1C and Table 3).
Although there were some differentially altered chromosomal segments between these
age-of-onset groups, they were not as high in proportion as in other locations, with a slight
predominance for LORC (Table 4 and Table S1). In this last group losses in 1p36.32-36.13 and gains in
5q13.2 are the most frequent.
Table 4. Summary of the main specific differential chromosomal regions between each age-of-onset
group, for each colon location.
Chromosomal
Segment RIGHT-SIDED
LEFT-SIDED
COLON RECTUM
EO
(n = 13)
LO
(n = 35)
EO
(n = 27)
LO
(n = 19)
EO
(n =2 0)
LO
(n = 32)
% % % % % %
chr1 p32.3-22.2 0 51
chr1 p21.3-11.2 0 51
chr2 p25.2 0 51
chr2 p11.2 54 20
chr10 q11.21-11.22 70 23
chr14 q11.1-11.2 85 37
chr16 p13.12-13.11 54 11
chr17 p11.2 62 29
chr18 p11.32-11.21 0 54
chr18 q21.1-21.1 8 51
chr18 q21.31-21.33 8 54
chr7 q11.22-21.11 15 63
chr7 q22.1-31.33 15 57
chr7 p12.2-11.2 15 54
chr7 q11.21 15 54
RIGHT COLON
chr9 q12-13 0 51
chr9 q33.3 62 29
chr9 q34.12-34.13 62 29
chr13 q11 8 51
chr21 q22.3 62 26
chr1 p12-q21.1 63 10
chr5 q13.1-13.2 67 16
chr9 p12-q24.22 59 21
chr9 q31.3-33.1 52 16
chr11 p11.12-q12.1 63 21
chr11 q14.1-14.3 59 21
chr15 p11.1-q11.2 0 26
chr19 p13.12-12 59 26
LEFT COLON
chr1 p36.32-36.13 5 41
chr1 p36.23-36.22 37 12
chr3 p21.31-21.1 42 32
chr5 q13.2 5 53
RECTUM
EO: Early-onset; LO: Late-onset; Chr: chromosome; Green: gained regions; Red: lost regions. Percentages shown in
bold indicate frequencies that are at least twice as high in one age-of-onset group as in the other.
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3. Discussion
CRC is a heterogeneous disease with different outcomes and drug responses. Subclassification
according to the age of onset and tumor location may have applications in terms of diagnosis,
prevention and therapy. We recently published differential features for EOCRC and LOCRC separately,
according to tumor location, and some interesting subsets within these age-of-onset groups became
manifest [9,11]. More interesting, however, was the possibility that both factors, age of onset and colon
location may differentiate CRC.
In right colon cancers, the differential phenotypes for both age groups are clearly correlated
with their molecular basis. Right-sided early-onset cases showed important LS features (poorly
differentiated tumors, a higher mean number of polyps, the familial component of LS-related
neoplasms), all of which are likely to be associated with the 30% of MSI due to germline mutations in
MMR genes; these tumors have a relatively low CIN but are CIMP-high. The late-onset subset was
mainly present in females, with sporadic features, and only 18% of cases were MSI; this was seldom due
to LS but mostly because of BRAF mutations. In spite of the higher CIN of right-sided LOCCs, the two
most frequently occurring differential regions (1q21 and 10q11.21-11.22) were observed in early-onset
cases. Increased alterations in 1q21 have been found before in EOCRC, although the criterion of tumor
location was not applied [13], while 10q11.21-11.22 is a region where the RET gene is located [14].
Another important aspect that should be underlined is the presence of losses in 14q11.1-11.2. Here the
NDRG2 gene is located, a tumor suppressor gene that has been associated with c-MYC and the TGF-β
pathway in colorectal carcinogenesis [15,16], and its epigenetic silencing promotes tumor proliferation
and invasiveness [17].
Left-colon tumors showed predominantly differences according to CIN (mainly whole
chromosomes altered). The most reliable clinical features were associated with the late-onset subgroup,
showing an important tendency to develop polyps as well as Multiple Primary CRC, in contrast with
the early-onset subgroup. Nevertheless, left-sided EOCCs showed the higher CIN, as well as some
differential CNAs, few of which have been associated previously with other features of CRC or the
early-onset of cancers. As we mentioned before, losses in 1q21.1-21.2 are found significantly more
in EOCRC [13]; losses in 11q14.1-14.3 have been associated with aggressive behaviors and familial
linkage, albeit in prostate cancers [18]; gains in 19p13.12 may be related with NOTCH3 expression
or function [19]. In addition, 11q14.1 harbors GAB2, a gene involved in Epithelial to Mesenchymal
transition, and more importantly, in the development of lymph-nodes invasion and metastasis [20].
Differences within rectal cancers are more prominent in the early-onset subset: later-stages at
diagnosis, less association with polyps, and more than half of them associated with a familial LS
component, although all of them are MSS. Only the CIMP-High-MSS category (36%) within LORC
is noteworthy. Only a few differential chromosomal segments appeared at high rates, and the most
frequent were associated with LORC; one of these, gains in 5q13.2, involves a segment associated with
rectal metastatic carcinomas [21].
Finally, we wanted to assess to which categories our location and age-of-onset subgroups
corresponded when comparing them with the recent consensus molecular classification of the CRC
subtyping consortium [22]. Since consensus molecular subtype 1 (CMS1 or MSI immune) is mainly
located in the right colon, we compared both age groups. As CMS1 characterized by MSI, this is clearly
related to both age groups, but mainly with the right-sided early-onset subgroup. The other features
are shared by the separate groups individually. While right-sided EOCC is linked with CIMP-High
and a low prevalence of somatic CNAs or CIN, right-sided LOCC showed BRAF mutation, high
grade of differentiation, predominance in females, and worse survival after relapse, in agreement with
recent studies showing worse prognosis of patients with MSI and recurring BRAF-mutant CRC [23–25].
In our study, the location group within EOCRC that had the best prognosis was the right colon, while
for LOCRC it was the left colon.
Consensus molecular subtype 2 (CMS2 or Canonical) is the most frequent and is defined by
somatic copy number alterations (SCNAs) in a larger proportion than in the other subtypes, by being
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mainly left-sided and by having a larger proportion of long-term survivors. Compared to our study,
the first three characteristics are clearly connected with left-sided EOCC and only the last with
left-sided LOCC.
Consensus molecular subtype 3 or metabolic type is characterized by MSI, CIMP-Low and low
CNA. Some features are associated with EOCRC (left colon with CIMP-low and MSI, and rectum also
CIMP-low), and others with left-sided LOCC and LORC, respectively (low CNA and CIMP-High).
Consensus molecular subtype 4 or mesenchymal type exhibits SCNA high, is diagnosed at
more advanced stages and show worse relapse-free and overall survival. Rectal tumors mainly with
early-onset could be classified in this molecular subtype. This point about rectal tumors deserves a
separate consideration to the extent that CMS classification mainly focused on right versus left colon
cancer, and only a few rectal cancers were included. The study of rectal cancer within EOCRC may
arise especially significant, as this subtype is the one that is increasing more remarkably in the last
years [26,27]. Other important points to take into account are that it has the worse prognosis for both
age-of-onset subgroups and that rectal cancer is a different disease than colon cancer. [28]. Efforts are
needed in order to identify with enough cases the group of the aforementioned classification where
rectal cancer could be framed if a new category does not arise as a result of this analysis.
However, our results and their correlative implications should be considered cautiously given the
limited sample size of the groups. Additional studies with a larger sample size should be developed to
confirm our findings.
4. Materials and Methods
4.1. Families, Samples and Data Collection
Between January 2002 and December 2008, a total of 82 consecutive individuals with CRC
diagnosed at an age of 45 years or younger (EOCRC) (we excluded 6 cases diagnosed with familial
adenomatous polyposis), and 97 consecutive patients with CRC diagnosed at an age of 70 years or
older (LOCRC), were collected at our institution. They were considered the index case of each family.
The age of 45 years or younger was chosen as an inclusion criterion because although there is no
consensus on a specific age, according to the literature, it is the age range where the majority of genetic
and phenotypic alterations are found. The age of 70 years or older was chosen as an inclusion criterion
because according to the World Health Organization, 65–70 years old is the cut-off point from which a
patient is considered older. Patients between 45 and 70 years of age were not included since, according
to the literature, cases may behave like late genetic syndromes or attenuated or more frequently as
sporadic tumors, thus overlapping with both groups. This may be a cause of confusion factor that
leads to false conclusions [29–32].
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of the “12 de Octubre” University Hospital. Personal and
clinicopathological information was obtained including age of onset, gender, location of the CRC
(right/left colon or rectum), grade of cell differentiation (low, medium or high), mucin production,
the presence of “signet ring” cells, TNM stages (6th version), the existence of polyps during
follow-up, type of polyps (adenomatous, hyperplastic or mixed), the presence of synchronous or
metachronous CRCs (SCRC or MCRC), and primary multiple neoplasms in the index case. The tumors
(adenocarcinomas) were pathologically confirmed by a single pathologist.
Right colon tumors have been defined as those ranging from the caecum to the proximal two-thirds
of the transverse colon and left colon tumors as those ranging from the distal third of the transverse
colon, including the splenic flexure, to the sigmoid colon. Rectal cancers are defined as those until
16 cm from anal verge (rectosigmoid junction).
To analyze the antecedents of cancer, families were classified into four groups: (a) families fulfilling
the Amsterdam II criteria for Lynch syndrome (LS) [33]; (b) families with mainly aggregation—at least
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one in first-degree or two in second-degree family members of LS-related neoplasms; (c) families with
mainly aggregation of LS-unrelated neoplasms; (d) cases without oncological antecedents; these were
considered sporadic cases.
Follow-up was at least 5 years from surgery; DFS and overall survival (OS), recurrence and
cancer-related death were recorded for each case and were included in the different attached tables as
a mean.
4.2. Microsatellite Instability and Mutational Analysis
A microsatellite instability (MSI) analysis was performed using the Bethesda panel [34],
as published before [3]. Tumors were considered as MSI when showing high-frequency MSI (MSI-H;
two or more of the five markers showing instability), while the rest (including MSI-L) were classified
as MSS.
MSI cases were screened for germline mutations in the mismatch repair (MMR) system genes
MLH1, MSH2 and MSH6 as previously reported, with minor modifications [35].
Sporadic MSI cases were identified by determining the methylation status of the MLH1 gene
promoter, as well as assessing the V600E mutation in the BRAF gene. The methods used were described
previously [4].
4.3. Analysis of CpG Island Methylation Phenotype Panel
Methylation status of promoter regions of the CpG island methylation phenotype (CIMP)
panel genes CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1 were
analyzed as published before [4]. CIMP-High was defined as the presence of ≥6/8 methylated
promoters, CIMP-Low as 1/8 to 5/8 methylated promoters, and CIMP-0 as the absence (0/8) of
methylated promoters.
4.4. Molecular Classification
Based on the MSI and CIMP status, we divided both age groups into four categories because
differences between MSI-L and MSS are subtle and differences between CIMP-Low and CIMP-0 are also
subtle: (MSI/CIMP-High); (MSI/CIMP-Low/0); (MSS/CIMP-High); and (MSS/CIMP-Low/0) [12].
4.5. Chromosomal Instability. Array Comparative Genomic Hybridization (aCGH)
A CGH was performed using oligonucleotide microarrays (Roche NimbleGen, Inc., Reykjavik,
Iceland) in order to identify copy number alterations (CNA) for both age-of-onset subgroups and has
been described before [10]. The degrees of genomic instability were also described in that same study.
Both datasets were included in the gene expression omnibus (GEO): LOCRC (GSE108166) and EOCRC
(GSE108220).
4.6. Statistical Analyses
Continuous variables were expressed as mean values plus/minus standard deviation (SD), and
categorical variables were expressed as the number of cases and their percentage. Differences were
considered significant when p < 0.05. For associations between colon location and other discrete
variables, statistical analyses were performed using Pearson’s chi-square (χ2) test for parametric
variables, and Fisher’s exact test for non-parametric variables. When those features were continuous
variables, Student’s t-test was used. The SPSS v.11.5 for Windows (SPSS, Inc., Chicago, IL, USA)
statistical package was used.
For the CGH analysis, both univariate and multivariate analysis was carried out to identify
significant minimum regions. Regarding the univariate analysis, unconditional logistic regression was
done for each candidate region. For the multivariate analysis, each of the regions was tested separately,
including other relevant clinical variables. Location was considered a factor in all analyses carried out.
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We selected only regions larger than 1 Mb, to avoid any possible bias. This analysis was performed in
R Statistical Software [36].
5. Conclusions
In our opinion, dividing CRC according to both location and age-of-onset criteria is meaningful,
not only because it homogenizes the resulting categories, but also because it facilitates new approaches
in those subsets of which the molecular basis remains as yet unknown: high CIN left-sided EOCC,
left-sided LOCC with multiple primary neoplasms, or EORC with a familial component and advanced
stage at diagnosis. The subclassification also helps to define clinically which tumors are more likely to
show certain already described molecular alterations, such as for example changes affecting NDRG2
or GAB2. Comparison with the consensus molecular classification also confirms the importance
of considering both criteria when studying CRC. With the confirmation across larger studies, new
therapeutical algorithms could be defined according to the classification of the age-of-onset and the
location of the tumor.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/4/
968/s1. Table S1: Differential chromosomal regions between each age-of-onset group, for each colon location.
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aCGH array of Comparative Genomic Hybridization
CIMP CpG Island Methylator Phenotype
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CRC Colorectal cancer
CMS Consensus Molecular subtype
CNA Copy Number Alterations
DFS Disease-Free survival
EOCC Early-onset colon cancer
EOCRC Early-onset colorectal cancer
EORC Early-onset rectal cancer
GEO Gene Expression Omnibus
LOCC Late-onset colon cancer
LOCRC Late-onset colorectal cancer
LORC Late-onset rectal cancer
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MCRC Metachronous colorectal cancer
MMR Mismatch Repair
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MSS Microsatellite stability
OS Overall survival
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SCRC Synchronous colorectal cancer
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